ALSO NOTED: Nycomed, Ceremed sign deal; Optimer raises $35.9M in private placement; GSK braces for cuts; and much more...

> Nycomed and Ceremed have signed a licensing and distribution pact for Ostene, a product designed to stop bone bleeding in surgery. Release

> Optimer Pharmaceuticals has raised $35.9 million from the private placement of 4.6 million newly issued shares of its common stock, at a price of $7.80 per share. Release

> The axe is about to drop at GlaxoSmithKline. The drug maker reported a 5.8 percent drop in profits to $2.77 billion--partly due to generic competition, but largely from a 48 percent slide in Avandia sales. Report

> Roche's siege on Amgen anemia-drugs territory is ending with a whimper. A jury ruled that the Swiss drug maker's Mircera product infringes three Amgen patents. Short of "evaluating its legal options" in hopes of a valid appeal, there's little Roche can do to fight back now. Report

> The cold-drug controversy is widening. Now, the FDA has asked an advisory panel to investigate phenylephrine, a new decongestant ingredient in many over-the-counter remedies. Report

> Gene mutations in the A beta protein are assisting these proteins in clumping together, which in turn is promoting Alzheimer's, according to a scientific team at UCLA. Report

> A molecular mechanism at work during periods of stress may shed light on developing new therapies for post-traumatic stress disorder and other conditions. Report

> Pfizer has closed its La Jolla campus due to the fire emergency in California. Release

And Finally... The race is on for muscle-enhancing therapies. Report